<DOC>
	<DOCNO>NCT02142049</DOCNO>
	<brief_summary>This Phase 1b/2 , open-label , non-randomized multicenter study assess safety efficacy ibrutinib lenalidomide combination DA-EPOCH-R subject relapsed/refractory Diffuse Large B-cell Lymphoma ( DLBCL ) . This study conduct 2 part treatment administer 3-week ( 21-day ) cycle 6 cycle . A standard 3+3 design employ Part 1 determine maximum tolerate dose ( MTD ) , define dose use Part 2 .</brief_summary>
	<brief_title>Ibrutinib Lenalidomide With Dose Adjusted EPOCH-R Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Major inclusion criterion : Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Pathologically confirm relapsed/refractory DLBCL Subjects must ≥1 measurable disease site CT scan ( ≥ 1.5 cm long dimension ) . Adequate hepatic renal function : AST ALT ≤2.5 x ULN Serum Creatinine ≤ 2.0 mg/dL creatinine clearance ≥60 mL/min/1.73 Bilirubin ≤1.5 x ULN Adequate hematologic function : ANC &gt; 1,000 cells/mm3 Platelets ≥75,000 cells/mm3 Hemoglobin ≥8.0 g/dL Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) must ≤1.5 x upper limit normal range ( ULN ) Must register Revlimid REMS™program willing comply requirement Revlimid REMS™ . Major Known central nervous system lymphoma Any chemotherapy , external beam radiation therapy , anticancer antibody within 2 week Radio toxinimmunoconjugates within 10 week Prior allogenetic stem cell ( organ ) transplant within 6 month evidence active graftversushost disease requirement immunosuppressant within 28 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>ABC</keyword>
	<keyword>GCB</keyword>
	<keyword>Primary Mediastinal B-cell lymphoma</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>EPOCH</keyword>
</DOC>